Degarelix Evidence Guide
Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.
Our Take
Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios.
- Evidence context
- Advanced prostate cancer androgen deprivation, rapid testosterone suppression, GnRH antagonist pharmacology
- Evidence grade
- Level A
- Confidence
- High
- Reference context
- Regulatory label reference: 240mg subcutaneous (two 120mg injections) loading dose, then 80mg subcutaneous monthly
Benefits and Evidence
- Testosterone Suppression: Level A, includes human evidence - Rapidly achieves and maintains castrate testosterone levels (<50 ng/dL) in >98% of patients. Faster onset than GnRH agonists without initial testosterone flare.
- Prostate Cancer Control: Level A, includes human evidence - Phase 3 trials demonstrate non-inferiority to leuprolide for testosterone suppression and PSA reduction in advanced prostate cancer patients.
- Cardiovascular Events: Level B, includes human evidence - Some evidence suggests lower cardiovascular event rates compared to GnRH agonists, particularly in patients with pre-existing cardiovascular disease.
Side Effects and Warnings
- Injection site reactions (pain, erythema, swelling)
- Hot flashes
- Weight gain
- Fatigue
- Increased liver enzymes
- Injection site reactions occur in ~40% of patients
- QT prolongation possible - monitor ECG in at-risk patients
- Hyperglycemia and diabetes risk with long-term androgen deprivation
Research Dosage References
- <strong>Subcutaneous injection</strong> - 240 mg (loading dose) - Once (first dose) - Loading dose administered as two 120 mg injections at different abdominal sites.
- <strong>Subcutaneous injection</strong> - 80 mg - Every 28 days (maintenance) - Maintenance dosing begins 28 days after loading dose. Administered in the abdominal area.
Mechanism of Action
Degarelix works through competitive antagonism of GnRH receptors: 1. GnRH receptor blockade: Binds competitively to pituitary GnRH receptors, preventing endogenous GnRH from activating them. 2. Immediate LH/FSH suppression: Rapidly decreases luteinizing hormone and follicle-stimulating hormone without the initial surge (flare) seen with GnRH agonists. 3. Testosterone suppression: Achieves castrate levels of testosterone within 1-3 days of first injection. 4. PSA reduction: Leads to rapid decline in prostate-specific antigen levels, reflecting reduced tumor stimulation.
Legal Status
FDA-approved for the treatment of advanced prostate cancer. Available by prescription only. Marketed as Firmagon by Ferring Pharmaceuticals.
Primary Sources
Quick Answers
Where is the strongest evidence for Degarelix?
Degarelix (Firmagon) is FDA-approved for advanced prostate cancer with Phase 3 data demonstrating faster testosterone suppression to castrate levels than LHRH agonists (within 3 days vs. 3-4 weeks), without the initial testosterone flare. Multiple comparative trials establish it as a first-line option in patients requiring rapid androgen deprivation. A highly validated prostate cancer treatment with clear pharmacological advantages over GnRH agonists in specific clinical scenarios. Evidence context: Advanced prostate cancer androgen deprivation, rapid testosterone suppression, GnRH antagonist pharmacology.
What are the main side effects of Degarelix?
Degarelix side effects and warning signals include Injection site reactions (pain, erythema, swelling), Hot flashes, Weight gain, Fatigue, and Increased liver enzymes.
What evidence level is Degarelix?
Degarelix is rated Level A; the listed research status is FDA Approved.